-
In a multinational observational study, independent from pharmaceutical support and involving both academic and community treatment centers, long-term follow-up for chronic myelogenous leukemia (CML) patients who, after two years of imatinib therapy, were in complete cytogenetic remission was undertaken for a median of 5.8 years. Although side effects were common, only a very small percentage of patients discontinued the drug and the majority maintained their cytogenetic response. In fact, the incidence of second malignancies and overall survival were no different for the CML patients in this cohort than for the general population in Italy.
-
Limited data are available to guide the decision between up-front allogeneic hematopoietic cell transplantation (HCT) or imatinib on long-term outcomes for accelerated phase chronic myelogenous leukemia (CML).
-
A 71-year-old retired police officer was admitted through the emergency room with right upper quadrant pain and low-grade fever.
-
-
Anticholinergic drugs for COPD; pioglitazone for diabetes prevention; insulin degludec in Phase 3 trials; and FDA Actions.
-
Patients with localized but non-resectable lung cancer generally are considered candidates for other types of therapy including external beam or stereotactic radiation therapy, chemotherapy, or percutaneous ablation.
-
-
In assessment of acute chest pain in the emergency room, a new or "presumably new" left bundle branch block (LBBB) is considered as an electrocardiographic (ECG) equivalent to ST elevation.
-
Current guidelines recommend dual anti-platelet therapy (DAPT) with aspirin and a thienopyridine, such as clopidogrel, following percutaneous coronary intervention (PCI).
-
Current guidelines recommend hypothermia for comatose survivors of out-of-hospital cardiac arrest in whom return of circulation has been achieved.
